Slide 1: Corporate Overview
Corporate Overview June 2023 –Sidoti Virtual Conference © 2023 Forian Inc.
Slide 2: Cautionary Statement Regarding Forward-Looking Statements
Cautionary Statement Regarding Forward-Looking Statements This presentation may contain “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.
Slide 3: Mission
Mission Improve health outcomes and business performance through data science driven information and analytic solutions We apply sophisticated data management and data science capabilities to our comprehensive clinical data lake to identify unique relationships, create distinctive information assets
Slide 4: Investment Highlights
Investment Highlights 1. Strong team with extensive healthcare data management, analytics and delivery experience 2. One of the largest integrated, HIPAA-compliant, longitudinal, deidentified patient-level data lakes in the market and scalable technology 3. Significant and rapidly growing healthcare
Slide 5: Proven Leadership
Proven Leadership Max Wygod Adam Dublin Michael Vesey Edward Spaniel, Jr. Co-Founder, CEO and Co-Founder, Chief Strategy Chief Financial Officer Executive Vice President, Executive Chairman Officer and Director General Counsel & Secretary Jason Holden Rebecca Adams Paul Reuscher Anita Murrell VP, Co
Slide 6: Robust Clinical Data Lake
Robust Clinical Data Lake HIPAA-compliant, deidentified patient/customer-level longitudinal data asset covering 305M+ patients Data Product ~2B Annual ~300M Annual ~3B Annual Social Determinants of Health Payor Sourced Closed Claims Medical Claims Hospital Claims Pharmacy Claims 1.1M+ Monthly Physic
Slide 7: Best-in-Class Data Management & Data Science
Best-in-Class Data Management & Data Science Our cutting-edge data science technology efficiently organizes, normalizes, standardizes, validates and integrates complex structured and unstructured transactional data in a timely and cost-efficient manner, while increasing quality and utility Unparalle
Slide 8: Customer Use Cases: Span the Healthcare Lifecycle
Customer Use Cases: Span the Healthcare Lifecycle Forian collaborates with healthcare and life sciences companies, from early stages of R&D through commercialization, and provides integrated data products, real world evidence and insights, and advanced analytics to help identify opportunities, accel
Slide 9: Multiple Tailwinds Driving Massive Addressable Market
Multiple Tailwinds Driving Massive Addressable Market Healthcare Necessity of Adoption of Estimated Global Healthcare Spend Data-Driven Value-Based Analytics Market ($B) – 22% CAGR Increasing Insights Care Healthcare spend in Patient outcomes are the US will grow by 5% Companies are becoming critica
Slide 10: Growth Opportunities
Growth Opportunities • Organic • Sales and marketing investments will drive continued new pharma client acquisition. • Leverage positive client experience to upsell/cross-sell additional information products and analytics solutions • Source incremental data to expand the potential use cases for our
Slide 11: Financials
Financials 11 © 2023 Forian Inc.
Slide 12: Full Year 2023 Outlook
Full Year 2023 Outlook Expect 2023 Healthcare Information Revenue growth of 25% to 37% resulting in revenue in the range of $20.5 to $22.5 million Continued Improvement in Adjusted EBITDA(1), reaching positive Adjusted EBITDA contribution in the second half of 2023 The outlook provided above constit
Slide 13: Revenue and Adjusted EBITDA
Revenue and Adjusted EBITDA Three Months Ended Period-over- March 31, Period % 2023 2022 Change Unaudited Unaudited Total revenue $ 4,870 $ 3,535 38% Loss from continuing operations, net of tax $ (2,073) $ (10,318) 80% Income (loss) from discontinued operations, net of tax $ 8,934 $ (1,536) 682% Net
Slide 14: Adjusted EBITDA Trend
Adjusted EBITDA Trend Continued improvement in Adjusted EBITDA loss driven by revenue growth and cost management 14 © 2023 Forian Inc.
Slide 15: Summary Balance Sheet Data
Summary Balance Sheet Data March 31, 2023 Cash and equivalents $40,004 Proceeds receivable – sale of discontinued operations $ 8,812 Net Working Capital $45,770 Convertible note and accrued interest (due 9/2025) $25,315 Shares outstanding 32,419 15 © 2023 Forian Inc.
Slide 16: Appendix
Appendix 16 © 2023 Forian Inc.
Slide 17: Non-U.S. GAAP Reconciliations Reported Net Income to Adjusted EBITDA
Non-U.S. GAAP Reconciliations Reported Net Income to Adjusted EBITDA $000's Q1 2023 Q1 2022 Explanation Net Income $ (2,249) $ (10,318) Adjustments Depreciation & amortization 38 15 includes accelerated vesting related to Stock based compensation 1,828 7,614 separation agreements Change in fair valu
Slide 18: Reconciliation of U.S. GAAP to Non-GAAP Financial Measures
Reconciliation of U.S. GAAP to Non-GAAP Financial Measures This presentation includes a non-GAAP measure, which we define as financial information that has not been prepared in accordance with U.S. GAAP. The non-U.S. GAAP financial measure provided herein is earnings before interest, taxes, non-cash